###### Strengths and limitations of this study

-   This prospective, multicentre study in a limited-resources environment aims to characterise value of neonatal sepsis diagnosis and prognosis biomarkers in a high-risk gestational malaria (GM) area.

-   The identified biomarkers through this study could provide new diagnostic and prognostic tools to identify immunosuppressed newborns at risk of neonatal sepsis.

-   Clinical and immunological phenotypes, and functional characterisations of a population with high risk of neonatal sepsis brings new insight to understanding the clinical and immune consequences of GM.

-   Lack of biological antenatal malaria documentation in the hospital arm may limit the extrapolation to the first and second trimester GM impact.

Introduction {#s1}
============

Sepsis remains the first cause of perinatal morbidity worldwide affecting more than 3 million neonates every year.[@R1] Nearly half of neonatal deaths in sub-Saharan Africa are due to sepsis.[@R2] In addition to neonatal sepsis, sub-Saharan Africa and South Asia that encompass 52% of world global live births, have an overweighed proportion of prematurity, which represents 60% of all preterm births worldwide.[@R3] Low- and middle-income countries (LMIC) are supporting most of these neonatal morbidities and the societal and economic impacts are high, hampering most initiatives that target promotion of neonatal and paediatric health.[@R5] Among others factors associated with neonatal infection, frequent endemic parasitic infections such as malaria, toxoplasmosis and schistosomiasis affect fetal and perinatal growth and development. Its specific impact on early childhood immunity is recognised and may explain altered vaccination response as well as increased risk of infection.[@R7] During gestational malaria (GM), the sequestration and cytoadhesion of infected red blood cells within intervillous space of the placenta will lead to local inflammatory responses and alteration of placental functions, and subsequently promote intrauterine growth restriction and prematurity.[@R10] In addition, in utero exposure to *Plasmodium falciparum* antigens impacts the newborn immune development[@R12] and is a risk factor predisposing to malaria and other infections during the first year of life.[@R14]

Understanding fetal immune maturation and more specifically during the last 3 months of pregnancy is a prerequisite to an accurate interpretation of neonatal response to infection.[@R16] To respond to pathogens, newborns depend essentially on their innate immune system. The Toll-like receptors (TLRs) represent the first line of defence and play an important role in orchestrating regulatory and inflammatory responses to pathogens and in initiating specific T and B cell responses.[@R17] Increased risk of early and late neonatal infection and impaired host response seen in premature infants is related to altered innate immune functions.[@R20] Although the underlying immunological basis are not well studied, small for gestational age (SGA) is also a recognised risk factors of neonatal infections.[@R23] Defective innate immunity seen in premature infants is strongly correlated with the extent of immaturity where extremely low birth weight infants (ie, \<28 weeks of gestational age) have a merely absent innate immune response.[@R21] This state of 'innate' immunodepression, although potentially reversible, shares many similarities to 'acquired' immunodepression seen in critically ill and septic patients.[@R25] Currently, the most robust and reproducible marker of immunodepression is the measurement of monocytic HLA-DR surface expression (mHLA-DR). Extended literature has correlated its level during the course of disease to 28 days mortality and occurrence of secondary infections.[@R28] Recently, two transcriptional biomarkers were shown to identify similarly those conditions. *CD74*, coding for the γ chain (Li chain) of class II CMH and *CX3CR1*, the fractalkine receptor, were shown to be associated with mortality and/or the occurrence of secondary infections.[@R29] Currently, less data exist on mHLA-DR in neonates. Although not found in all series, mHLA-DR seems to be reduced in premature infants compared with term infants and predicts both early-onset neonatal sepsis (EONS) and late-onset neonatal sepsis (LONS) with an acceptable accuracy (receiver operating characteristic area under the curve 0.78; 95% CI: 0.61 to 0.92).[@R21] No data exist on the value of both *CD74* and *CX3CR1* transcripts for prognostication of neonatal sepsis. However, current understanding of sepsis pathophysiology and, more specifically, sepsis-induced immunodepression, sustain the exploration of this specific condition, particularly in patients where immunodepressed states are known to be part of the pathophysiology and impact severity. Exploring biomarkers for sepsis diagnosis and prognostication in neonates exposed to GM may prove to be particularly relevant. Both a better characterisation of the immunodepressed state encountered in those patients and optimisation of sepsis diagnosis could be expected by using combined biomarkers, mixing both sepsis diagnosis and immunosuppression identification.

Rationale of the study {#s2}
======================

From a clinical perspective, increased incidence of neonatal sepsis, more specifically to Gram-negative bacteria, has been repetitively shown in sub-Saharan infants.[@R32] Effect of GM and prematurity are well known factors associated with bacterial infection susceptibility.[@R1] Although several studies have shown that in utero *P. falciparum* exposure impairs the immune development of newborns,[@R34] making them more likely to develop malaria and other infections in their first months of life,[@R12] no study has detailed its immunological impact so far. The increased risk of neonatal sepsis has significant collateral consequences such sepsis overdiagnosis, overuse of broad-spectrum antibiotics and development of antibiotic resistance. In such clinical context, antibiotic stewardship is central but limited by the lack of accurate diagnostic tools. Use of biomarkers of neonatal sepsis in LMIC is limited not only by economic perspectives but also due to the lack of validation in those populations. Only few epidemiological data exploring those conditions exist, as large prospective study requires important clinical and financial support to overcome limited resources in LMIC.

From a biological perspective, both GM and prematurity could have similar impact on the newborn's immune system such as impaired TLRs and T regulatory cells responses explaining this increased susceptibility to infection.[@R34] Those altered immune responses, similar to a state of immunodepression, may impact the accuracy of biomarkers for EONS. GM-induced and prematurity-induced immunodepression were partially characterised by immune functional assay (cytokines release after ex vivo Pathogens-Associated Molecular Patterns (PAMPs) stimulation) and peripheral blood mononuclear cell (PBMC) phenotyping, but most underlying molecular mechanism still remains to be identified.[@R38] Better characterisation of the state of immunosuppression may help in optimising neonatal sepsis diagnosis and management in addition to opening a potential avenue for immune stimulation and restoration of efficient response to pathogens.[@R21]

Hypothesis {#s2-1}
----------

To overcome the lack of epidemiological data on GM and neonatal sepsis as well as on infant's immune response, the SEPSIS study propose to prospectively follow infants born in an urban and suburban malarial endemic area from the peripartum period to 3 months of age. Biological biomarkers, PBMC phenotyping as well as immune functional assays will be performed at delivery and during the follow-up. Reference values will be determined and correlation between the biological measurements and occurrence of clinical neonatal sepsis performed. To explain the increased susceptibility of infants with GM, we hypothesised that in utero exposure to *P. falciparum* antigens modifies the TLRs transcriptional response (specifically of the endotoxins recognition complex myeloid differentiation factor 2: TLR4) and the Treg and Breg function when exposed to Gram-negative bacteria, which would explain the state of immunodepression in their first month of life. Therefore, besides phenotypic and functional characterisation of the immune response, specific analysis of the molecular mechanisms triggering GM-mediated immunodepression will be investigated. The SEPSIS project will provide validated reference values for current and new biomarkers of sepsis and GM-induced immunosuppression in sub-Saharan Africa, and may open new perspective in global understanding of sepsis in immunosuppressed infants.

Aims and objectives {#s2-2}
-------------------

The primary objective of this study is to evaluate procalcitonin (PCT) for neonatal sepsis diagnosis and evaluate *CD74* and *CX3CR1* to prognose neonatal sepsis in GM endemic area. The secondary objectives are:

-   To evaluate markers association (interleukin (IL)-6, TNFα, IL-10, IP10) to improve diagnosis and prognosis accuracy of PCT, and *CD74* and *CX3CR1.*

-   To characterise the epidemiology of neonatal sepsis in this population.

-   To characterise the effect of GM on the evolution of the innate and adaptive immune profiles between birth and 3 months of life in infants.

-   To evaluate the molecular effect of GM on innate immune response to PAMPs.

The results of this large translational project in sub-Saharan Africa, where malaria, prematurity/SGA and neonatal infections are major public health issues, will contribute:

-   To better understand the consequences of prematurity and GM on the neonatal immune system and the associated immunosuppression.

-   To test the use of biomarkers (including immunosuppression biomarkers) to optimise diagnosis and severity assessments of neonatal sepsis in a population with GM-induced immunosuppression and obtain reference values in sub-Saharian Africa.

-   To evaluate experimental ex vivo therapy to reverse GM-induced immunosuppression.

Methods and analysis {#s3}
====================

SEPSIS is a prospective longitudinal, multicentre observational study conducted in the Abomey-Calavi, Sô-Ava and Cotonou districts in South Benin ([figure 1](#F1){ref-type="fig"}).

![Geographical location of the six study centres in the Sô-Ava, Abomey-Calavi and Cotonou districts in Benin.](bmjopen-2020-036905f01){#F1}

Study population {#s3-1}
----------------

In this project, patients will be enrolled from (1) three suburban health centres (the suburban arm) in order to follow low-risk delivery and (2) three urban hospitals (the Hospital arm) in order to follow infants born from high-risk delivery. In both arms, only women living in the Abomey-Calavi region will be recruited to facilitate the follow-up and to work on infant from the same geographical area.

-   The suburban arm aims to follow low-risk deliveries and includes a part of children born to mothers previously included in the RECIPAL cohort (that aims to evaluate the impact of GM on the fetal growth).[@R41] In this study arm, out of 411 pregnant women, 273 will be followed until delivery for the study. Because of a delay in the timing between both projects, only the last 160 newborn of the RECIPAL cohort will be enrolled. The expected frequency of GM and prematurity are 40% and 12%, respectively. This cohort will provide specimen from the child and information on mother's pregnancy and newborn's follow-up.

-   The Hospital arm aims to follow children born to mothers with high risk of developing neonatal sepsis. All consecutive deliveries with any perinatal risk of infection were included in the study. Those perinatal risk factors were as follows: prematurity, prolonged ruptures of membranes (\>18 hours), maternal fever and/or infection, fetal distress, neonatal resuscitation at delivery and multiple gestation. Children will be recruited at birth in three main university hospitals: Centre Hospitalier Universitaire de la Mère et de l'Enfant Lagune (CHUMEL), Centre National Hospitalier Universitaire (CNHU) in Cotonou and the Centre Hospitalier Universitaire Zone Abomey Calavi / Sô Ava (CHU ZAC) in Calavi. Approximately 420 children will be followed with the inclusion and exclusion criteria presented in [figure 2](#F2){ref-type="fig"}.

-   The study is coordinated by the Institut de Recherche Clinique du Bénin (IRCB).

![Schematic design of the sepsis study illustrating inclusion, planned biological analysis and follow-up time points.](bmjopen-2020-036905f02){#F2}

All children from both arms will be followed clinically on a bimonthly base during the first 3 months of life. The length of the follow-up was decided as being the most risky period in terms of susceptibility to sepsis, neonatal mortality and the development period for the immune responses.[@R17]

The clinical follow-up of these children will be conducted during the first 12 weeks of life during home visits or in healthcare centres. Newborn from the hospital arm will also be followed in case of hospitalisation for EONS. We expected that hospitalised newborns will stay from 1 to 10 days at the hospital after birth before going back to their home. The follow-up will consist of scheduled home visits and unscheduled emergency visits if the infant is sick.

1.  Newborns will have a full clinical examination by a trained nurse at birth and during home visits (Birth, Week (W)1, W2, W4, W6, W8, W10 and W12).

2.  Blood samples will be obtained at birth (cord blood), then at W1, W4, W8 and W12.

3.  All sick infants identified during systematic home or unscheduled visits will come for a visit to a healthcare centre, where additional blood sample will be obtained. Unscheduled visits will be called emergency visits in the rest of the document.

4.  Healthcare centres are only able to perform haemogram and blood smear. All infants with suspected sepsis needing additional therapeutic and diagnostic workup will be referred to the reference hospitals where sepsis workup can be performed. According to the clinical symptoms, the paediatrician will ask for specific bacteriological analysis to confirm a suspected infection.

Definition and neonatal sepsis diagnosis {#s3-2}
----------------------------------------

Neonatal sepsis diagnosis will be established by the local paediatrician based on the child clinical examination and initial workup including haemogram, C-reactive protein (CRP) and microbiological cultures (blood, cerebral fluids and urine). In the Hospital arm of the study, neonatal sepsis will be suspected in neonates with perinatal infectious risk factors, as previously described, and more than two of the following criteria being present: neutrophil count \<7500/mm^3^ or \>14 500/mm^3^, band form \>1500/mm^3^, immature/total neutrophils ratio \>0.16, platelets count \<1 50 000/mm^3^ and CRP \>10 mg/L. Suspected neonatal sepsis will be considered as clinical sepsis when the following clinical signs are associated: temperature irregularity; respiratory distress or apnoea; seizures, altered tonus, irritability or lethargy; vomiting, altered feeding pattern, ileus; skin perfusion alteration, haemodynamic signs (tachycardia, hypotension); hypoglycaemic/hyperglycaemic, hyperlactatemia or identification of focal infection such as soft tissue infection or conjunctivitis. In the suburban arm, neonatal sepsis will be suspected if the child demonstrates clinical signs as mentioned. In such case, the child will be transferred to the hospital where further sepsis workup will be performed. Neonatal sepsis will be considered as EONS if occurring within the first 72 hours after delivery, and LONS thereafter. Neonatal sepsis diagnosis and subsequent management will be left at the discretion of the paediatrician in charge of the child. All newborns with a clinical diagnosis of sepsis will be subsequently adjudicated by two independent paediatricians (PT, ULT) and sorted into 'presumed sepsis' and 'definite clinical sepsis'. In addition to the full medical file review, microbiological cultures results will be monitored. Parallel to microbiological culture, we will use the specific BioFire Filmarray panels for all positive blood culture (Blood Culture Identification (BCID) panel) and cerebrospinal fluids (meningitis/encephalitis panel). All studied biomarkers will be kept blinded to the adjudication. In parallel, neonatal risk assessment will be scored using the Neonatal Sepsis Trial Network grid and patients scored from 1 to 3.[@R42] GM will be defined as a malaria infection during pregnancy or at delivery. For women in the suburban arm, malaria screening will be performed at each scheduled prenatal visit using a thick blood smear. Mothers from the Hospital arm will be screened only at the time of delivery. In this group, antenatal malaria will be established on the basis of mother's anamnesis. For both study arms, placental blood smear and mother's peripheral blood smear will be performed. The Lambaréné technique will be used to quantify parasitaemia with a detection threshold of five parasites per microlitre.[@R43]

Sample and clinical data collection {#s3-3}
-----------------------------------

Clinical and biological (biobanking) data dedicated to this project will be gathered according to [table 1](#T1){ref-type="table"}.

###### 

Clinical and biological data collection planning

                                  Mother   Birth   W01   W02   W04   W06   W08   W10   W12   Emergency
  ------------------------------- -------- ------- ----- ----- ----- ----- ----- ----- ----- -----------
  Patients characteristics                                                                   
   Inclusion/exclusion criteria            x                                                 
   Consent form                            x                                                 
   Demography                     x        x                                                 
   Reproductive and obstetric     x                                                          
   Anthropometry                  x        x       x     x     x     x     x     x     x     x
   Malaria in pregnancy           x                                                          
   Clinical examination           x        x       x     x     x     x     x     x     x     x
   Temperature                    x        x       x     x     x     x     x     x     x     x
   Pulse rate                              x       x     x     x     x     x     x     x     x
   Breathing rate                          x       x     x     x     x     x     x     x     x
   Breastfeeding and feeding               x       x     x     x     x     x     x     x     x
   Description of hospital stay                                                              x
  Biology                                                                                    
   Dry blood spot                 x        x                   x           x           x     x
   Blood smear                    x        x                   x           x           x     x
   Heparin tube sampling                   x       x           x           x           x     x
   Haemoglobin                             x       x           x           x           x     x
   TLRs stimulation                        x                                           x     x
   Plasma                                  x       x           x           x           x     x
   Procalcitonin                           x       x           x           x           x     x
   PBMC                                    x                                           x     x
   Paxgen tube sampling                    x       x           x           x           x     x
   Stool sampling                          x       x           x           x           x     x
   Placenta biopsy                         x                                                 

PBMC, peripheral blood mononuclear cell; TLR, toll-like receptor; W, weeks.

For the various biological tests to be performed in this study, the sample collection will allow us to establish several types of biobanking:

1.  Heparin plasma for the study of protein biomarkers.

2.  Supernatant from unstimulated whole blood and ex vivo stimulated with TLR ligands for the quantitative evaluation of cytokines release.

3.  Messenger RNA (mRNA) biobank extracted from cell pellet of unstimulated whole blood and blood stimulated with TLR ligands, preserved in PAXgene (Qiagen, Hilden, Germany) for the study of gene transcripts of TLRs and signalling pathways.

4.  mRNA biobank to study transcriptomic host biomarkers (RNA will be extracted from whole blood collected in PAXgene tubes).

5.  Biobanking of PBMCs isolated from cord blood and peripheral blood by gradient separation of Ficoll (Sigma, Darmstadt, Germany) density for the exploration of Treg and Breg cells function.

Biomarkers measurements {#s3-4}
-----------------------

This part of the study will consist of testing blood samples of the children from both arms to validate *CX3CR1, CD74*, IL-10, PCT, IP10, TNFα and IL-6. For transcriptomic biomarkers, after extraction of from whole blood using the QIAsymphony SP/AS automated system (Qiagen, Hilden, Germany) with the QIAsymphony PAXgene blood RNA kit (PreAnalytiX, Hombrechtikon, Switzerland), mRNA from *CD74* and *CX3CR1* will be quantified by quantitative PCR (Q-PCR) using *CD74/HPRT1* and *CX3CR1/HPRT1* prototype kits (bioMérieux, Marcy-l'Etoile, France) on an ABI7500 thermocycler (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Protein biomarkers associated with immunosuppression and inflammation (PCT, IL-6, TNFα, IL-10, and IP10) will be measured in heparinised plasma using the multiplex Ella platform (ProteinSimple, San Jose, California, USA).

Dynamic immune profiles {#s3-5}
-----------------------

Here, we plan to study the immune profile of the first 3 months of age. Biological samples will be used to determine and study the transcriptional and functional profiles of the innate and adaptive immunity. We foresee the following analyses:

1.  Ex vivo functionality of the innate response via TLRs stimulation. Whole blood stimulation with TLRs agonists (LPS, FSL1, Pam3CSK4, Flagellin, PolyI:C, CPG-ODN, Imiquimod and Resiquimod) (Sigma, Darmstadt, Germany). Proinflammatory and anti-inflammatory cytokines/chemokine (IL-6, IL-10, TNFα) in supernatants (eBioscience, Thermo Fisher Scientific, Waltham, Massachusetts, USA) and genes transcripts quantification by Q-PCR will be performed using a CFX90 thermocycler (Biorad, Hercules, California, USA). Analysis will be performed in selected patients divided into four groups (GM and sepsis, no GM and sepsis, GM and no sepsis, no GM and no sepsis). Patients will be selected from both study arms.

2.  Ex vivo functionality and phenotyping of Treg and Breg lymphocytes. Using flow cytometry (FACS Canto, Becton Dickinson, Franklin Lakes, New Jersey, USA), we will investigate different functional markers like the gut-homing α4β7 integrins, CD39 and CTLA4 immunosuppressive markers. Second, the frequencies of Treg and Breg producing intracytoplasmic IL-10 and TGFβ will be assessed in cord blood after mitogen or antigen ex vivo stimulation.[@R44]

Modulation of the host response against *P. falciparum* {#s3-6}
-------------------------------------------------------

In this part, we aim to design an ex vivo experimental model of co-culture assays to mimic a clinical situation of malaria and Gram-negative infections. The objective is to perform in vitro co-culture functional assays with various stimuli combinations (TLRs agonists and/or *P. falciparum*-schizonte extract) to highlight the mechanisms of endotoxins anergy observed in infants with GM.

Sample size and data analysis plan {#s3-7}
----------------------------------

To assess the accuracy of new biomarkers of sepsis (PCT) and immunosuppression (CD74 and CX3CR1): we estimated that of the 400 children, 40 would get an infection (fever) within 7 days after birth and 189 would get an infection within 3 months of follow-up (W2 to W12) after birth. With an expected proportion of 75% infection in PCT+ and 25% in PCT-- (knowing that the difference in proportions is probably even greater between the two groups), t68 subjects (34 in each group) will be required to reach a 99% power and risk of first kind of 5%, which shows that the size of this study (higher in both groups) will answer this question with a power reaching almost 100%. Statistical analyses were performed using R software V.3.6.1. Numbers and frequency were used for categorical data and means (SD) or medians (IQR) for continuous data. Categorical variables were compared using the χ^2^ test (or Fisher's exact test for small expected numbers). The distribution of continuous data was compared using Student's t-test (or the Mann-Whitney test when distribution was not normal) if the outcome was two groups, and analysis of variance (or the Kruskal-Wallis test when distribution was not normal) if not. OR and 95% CI were assessed using logistic regression models. An adjustment to the p values (q value) was performed using False Discovery Rate (FDR) correction (Benjamini-Hochberg). The independent variables initially included in the model were those associated with the infection of the newborn or infant in univariate analysis with p\<20% and a stepwise or backward procedure was applied to assess variables that were significantly and independently associated with the infection of the newborn or infant at 5% level. When the linearity hypothesis was not respected, the continuous variables were transformed into ordered data (clinically meaningful classes or median separation). To analyse the infection of the newborn or infant, we considered variables associated with the patient (history of maternal infections, gestational age, child's age, birth weight, prematurity, GM, SGA and other risk factors) and/or with the different biomarkers (PCT, *CD74* and *CX3CR1*). All reported p values are two-sided and the significance threshold was set at \<0.05. Other machine models (Random Forest, Decision Tree, Support Vector Machine and k-Nearest Neighbour) will be used to increase performance. For this purpose, the data will be divided into two parts: a training part (algorithm training) and a test part (to obtain performance).

Ethics and dissemination {#s4}
========================

Ethics approval {#s4-1}
---------------

The protocol, information documents and consent forms for legal representatives received approval from the ethical committee (CER-ISBA) in Benin (Approval code: CER-ISBA 85 - 5 April 2016). An amendment has been filed to extend the study to a second hospital cohort. This amendment was approved on 3 February 2017). This study complies with the Declaration of Helsinki principles of Good Practice and the Nagoya protocol.

Informed consent {#s4-2}
----------------

-   The study investigator who identified the child and the parents of the child will read the information document aloud and give them full details in the event of any questions.

```{=html}
<!-- -->
```
-   If the child\'s parents are literate, the information will be administered in French, and consent will be given to one of the parents (father or mother) of the child for proofreading. After reading and answering any questions from parents, the consent form will be signed. One of the parents and the interviewer will complete and sign the form in duplicate. One copy will be given to the parents and the second copy will be placed in the master file of the study.

```{=html}
<!-- -->
```
-   If the child's parents are illiterate, the information will be administered in the local language (Mainly, Fon, Toffin, Aizo or other). In addition, the information document will be given to an impartial witness, independent of the investigation and previously identified by the parents themselves, who will act as a signatory witness. This person may be a parent or guardian. After the parents\' questions have been answered, consent will be signed: one of the parents will put the fingerprint of the left index finger in place of the signature and the witness present throughout the parent information process will sign the consent to his turn. Finally, the investigator will complete and sign the consent. The form will be completed in two copies. The parents will keep a copy of the consent and the second copy will be kept in the master file of the study.

```{=html}
<!-- -->
```
-   The consents will be kept at the IRCB premises for 5 years.

Safety of participants {#s4-3}
----------------------

This study includes no serious foreseeable risk to the health of the children involved. The only potential risk is related to blood sample collection (maximum total blood per sampling 1 mL/kg, collected over all time points). In cases where children develop sepsis requiring hospitalisation, all related costs will be supported by the investigators.

Study management {#s4-4}
----------------

The study is coordinated by bioMérieux and a dedicated team composed from members of the entire consortium. The clinical trial was coordinated by the IRCB.

Data management and handling {#s4-5}
----------------------------

For each patient, a paper Case Report Form (CRF) including sociodemographic, anthropometric, clinical and paraclinical information will be completed by clinical assistants and healthcare providers. MS Access was used to gather all the data from this clinical study. RStudio V.1.1.383 (RStudio, Boston, Massachusetts, USA) will be used to perform the statistical analysis of data. All samples and initial processing of the biobanking will be performed at the IRCB. Subsequently, biobanking will either stay at the IRCB or be transferred to the Christophe Mérieux research centre in Grenoble, France, for further processing (*CD74* and *CX3CR1* Q-PCR; biomarkers dosing). Whole blood *ex vivo* stimulation will be transferred to the Institute of Integrative Biology of the Cell, Gif-sur-Yvette, France. Data set will be available from the IRCB.

Medical confidentiality {#s4-6}
-----------------------

All the data collected will be pseudonymised and covered by medical confidentiality. To protect the participant's confidentiality, samples will be de-identified. The investigator will ensure that confidentiality is maintained. Patients will only be identified by their initials and study number (ID code) on the observation books or on all other documents. These ID codes will be kept separately. Patient data, identified by the ID code will be stored separately. The investigator will ensure the retention of the identification list of patients included in the study. This includes at least the first page of the CRF and the Access databases (Microsoft, Redmond, Washington, USA). All the CRFs will be kept in the IRCB premises for at least 5 years in an air-conditioned container. As part of data processing, data consultation and data analysis performed in France, all patients at each site will be informed of the data processing procedure as well as their rights including the right of access to and the right of opposition to the transmission of the data.

Professional secrecy will be respected by all the persons participating in the conduct of this study. The manager, the investigator and all their collaborators undertake the responsibility to not transmit to a third party any of the confidential information obtained through this research, including information on the health status of the patients or about the current study.
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